AU2001230395A1 - Use of cox-2 inhibitors as gastroprokinetics - Google Patents

Use of cox-2 inhibitors as gastroprokinetics

Info

Publication number
AU2001230395A1
AU2001230395A1 AU2001230395A AU3039501A AU2001230395A1 AU 2001230395 A1 AU2001230395 A1 AU 2001230395A1 AU 2001230395 A AU2001230395 A AU 2001230395A AU 3039501 A AU3039501 A AU 3039501A AU 2001230395 A1 AU2001230395 A1 AU 2001230395A1
Authority
AU
Australia
Prior art keywords
cox
gastroprokinetics
inhibitors
gastroprokinetic
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001230395A
Inventor
Allen Wayne Mangel
Alan Naylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of AU2001230395A1 publication Critical patent/AU2001230395A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of a disorder ameliorated by a gastroprokinetic.
AU2001230395A 2000-02-01 2001-02-01 Use of cox-2 inhibitors as gastroprokinetics Abandoned AU2001230395A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0002336.6A GB0002336D0 (en) 2000-02-01 2000-02-01 Medicaments
GB0002336 2000-02-01
PCT/GB2001/000423 WO2001056573A1 (en) 2000-02-01 2001-02-01 Use of cox-2 inhibitors as gastroprokinetics

Publications (1)

Publication Number Publication Date
AU2001230395A1 true AU2001230395A1 (en) 2001-08-14

Family

ID=9884782

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001230395A Abandoned AU2001230395A1 (en) 2000-02-01 2001-02-01 Use of cox-2 inhibitors as gastroprokinetics

Country Status (8)

Country Link
US (2) US6759413B2 (en)
EP (1) EP1259239B1 (en)
JP (1) JP2003521516A (en)
AT (1) ATE357918T1 (en)
AU (1) AU2001230395A1 (en)
DE (1) DE60127537D1 (en)
GB (1) GB0002336D0 (en)
WO (1) WO2001056573A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0002312D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
DE60122939T2 (en) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford SUBSTITUTED ARYL COMPOUNDS AS NEW, CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS, AND USE PROCESSES
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0124459D0 (en) * 2001-10-11 2001-12-05 Novartis Ag Organic compounds
ATE522214T1 (en) * 2002-04-08 2011-09-15 Zeria Pharm Co Ltd THERAPEUTIC AGENT FOR NUTRITIONAL COMPETENCY DISORDERS IN THE STOMACH
US20040127537A1 (en) * 2002-06-26 2004-07-01 Gokarn Yatin R. Stable liquid parenteral parecoxib formulation
ES2263058T3 (en) 2002-08-19 2006-12-01 Glaxo Group Limited PIRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS.
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
FR2845917B1 (en) * 2002-10-21 2006-07-07 Negma Gild PHARMACEUTICAL COMPOSITION COMPRISING TENATOPRAZOLE AND ANTI-INFLAMMATORY
EP1572217B1 (en) 2002-12-12 2008-08-20 Nycomed GmbH Combination medicament of r,r-formoterol and ciclesonide
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
PL1670482T5 (en) 2003-09-16 2022-10-03 Covis Pharma Gmbh Use of ciclesonide for the treatment of respiratory diseases
US20070141156A1 (en) * 2005-12-21 2007-06-21 Uri Herzberg Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US8377906B2 (en) * 2004-06-04 2013-02-19 Ethicon, Inc. Compositions and methods for preventing or reducing postoperative ileus and gastric stasis
US20080086078A1 (en) * 2006-10-06 2008-04-10 Powell Darrel M Devices for reduction of post operative ileus
US20080085296A1 (en) * 2006-10-06 2008-04-10 Powell Darrel M Methods for reduction of post operative ileus.
JP2009084281A (en) * 2007-09-18 2009-04-23 Ethicon Endo Surgery Inc Method for reduction of post-operative ileus
JP6298472B2 (en) 2012-11-19 2018-03-20 ノバルティス アーゲー Compounds and compositions for the treatment of parasitic diseases
US8871754B2 (en) 2012-11-19 2014-10-28 Irm Llc Compounds and compositions for the treatment of parasitic diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9601442A3 (en) * 1995-07-25 1999-03-29 Panacea Biotec Ltd Nes antinflammatory and analgetic pharmaceutical compositions, containing nimesulid for transdermal use, and process for producing them
DE19623735C1 (en) 1996-06-14 1997-10-23 Meyer Lucas Gmbh & Co Additive for bakery products e.g. bread or rolls made from white flour
GB9709739D0 (en) * 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation
WO2000048583A2 (en) * 1999-02-19 2000-08-24 Pozen Inc. Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
RU2002119574A (en) * 1999-12-23 2004-01-10 Нитромед, Инк. (Us) Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions based on them and methods for their use

Also Published As

Publication number Publication date
ATE357918T1 (en) 2007-04-15
WO2001056573A1 (en) 2001-08-09
EP1259239A2 (en) 2002-11-27
JP2003521516A (en) 2003-07-15
US6759413B2 (en) 2004-07-06
EP1259239B1 (en) 2007-03-28
US20030022897A1 (en) 2003-01-30
US20040192694A1 (en) 2004-09-30
DE60127537D1 (en) 2007-05-10
GB0002336D0 (en) 2000-03-22
WO2001056573A8 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
YU5503A (en) Non-steroidal inflammation inhibitors
PT1940839E (en) Pyridopyrimidinone inhibitors of pi3kalpha
AP1699A (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
IL151588A0 (en) Inhibitors of dipeptidyl peptidase iv
MXPA02009706A (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts.
AU2002246728A1 (en) Carboline derivatives
MXPA05000122A (en) Compounds useful for the inhibition of aldh.
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
AU2002249890A1 (en) Carboline derivatives
AU2001288899A1 (en) Inhibitors of nadh:ubiquinone oxidoreductase
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
MXPA02012054A (en) Tetracyclic diketopiperazine compounds as pdev inhibitors.
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
TW200508199A (en) Novel compound
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
TW200508233A (en) Chk-1 inhibitors
AU2001265182A1 (en) Inhibitors of matrix metalloproteinases
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU2003234925A1 (en) TGF-Alpha EXPRESSION INHIBITORS
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
AU2003248710A1 (en) Methods of use for tripeptidyl peptidase ii inhibitors as anticancer agents
PT1276722E (en) NAFTAMIDINE-UROQUINASE INHIBITORS
PL359727A1 (en) Crystalline pharmaceutical